REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Although panelists expressed concerns about REMS misuse as barrier to competition, Republicans did not appear interested in the topic.

Imagine this scene: Republicans call a hearing to discuss how a federal agency handles a regulated industry. Company executives and government bureaucrats are present. Then the elected representatives from the party of small government don't tee up any questions for industry to offer its preferred solutions to the problems it sees with current regulations.

That's the situation the generic industry found itself in during a March 2 hearing by House Energy & Commerce Subcommittee...

Welcome to Pink Sheet

Create an account to read this article

More from Generics

More from Biosimilars & Generics